Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

TreatPreg Enhanced preventive antiparasitic treatment for better health of African pregnants and their babies

Coordinator
Eberhard Karls Universitaet Tuebingen, Germany
Runs
1 June 2025 to 31 May 2030
Status
Running
EU funding
€4.8m
Total cost
€4.8m
Partners
7 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101190861

What the project is doing

In the project's own words, from its summary on CORDIS.

Pregnant women in Africa are exposed to considerable health risks, with parasitic infections being a major threat. Schistosomes, soil-transmitted helminths, and malaria parasites are highly prevalent and polyparasite infections are common. In pregnancy, besides iron deficiency parasites are a key factor causing anaemia associated with an increased risk of maternal and infant morbidity and mortality. More than 50% of the pregnant women are affected by anaemia and an estimated 0.8 million pregnant women globally have severe anaemia.

Antenatal care is a health program to regularly deliver health services including preventive measures with the aim of improving maternal and newborn health. In terms of fighting parasitic diseases, WHO recommends to preventively treat soil-transmitted helminths, schistosomes and malaria parasites. In many endemic sub-Saharan African countries, however, these recommendations are often only partially implemented and not consistently applied in daily antenatal care.

Reasons are multifactorial but hesitation in administering multiple drugs this vulnerable population and the complexity of integrating the use of multiple drugs into the antenatal care schedule. On the other hand, data is accumulating that outweighs the potential risk of antiparasitic drug intake versus health benefits. The project aims to increase the uptake and integration of presumptive antiparasitic treatment during pregnancy to combat anaemia and improve health outcomes for pregnant women and their babies in sub-Saharan Africa.

To this end, a multi-country trial will assess the safety, tolerability and efficacy of co-administered antiparasitic drugs. Pharmacokinetic data, cost-effectiveness analysis and public health stakeholder’s involvement will further strengthen the case for future implementation of co-administered antiparasitic drugs in antenatal care schedules. Training in African scientific leadership will contribute to a critical mass of highly trained professionals.

Topics

Who is involved

OrganisationCityCountryRole
Eberhard Karls Universitaet TuebingenTuebingenGermanyCoordinator
Fondation Pour La Recherche Scientifique (fors)CotonouBJParticipant
Fondation Congolaise Pour La Recherche MedicaleBrazzavilleCGParticipant
Bernhard-Nocht-Institut Fuer TropenmedizinHamburgGermanyParticipant
Fundacion Privada Instituto De Salud Global BarcelonaBarcelonaSpainParticipant
Centre de Recherches Medicales de LambarénéLambarénéGAParticipant
Kwame Nkrumah University of Science and Technology KumasiKumasiGhanaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI